Under Atmanirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous COVID Vaccines. This is being implemented by the Department of Biotechnology, Govt. of India at Biotechnology Industry Research Assistance Council (BIRAC), New Delhi.
To augment the capacity of Indigenous production of Covaxin under the Mission, theDepartment of Biotechnology, Government of India in April 2021 provided financial support as Grant to vaccine manufacturing facilities for enhanced production capacities, which is expected to reach more than 10 crore doses per month by September 2021.
As part of this augmentation plan, the capacities of Bharat Biotech Limited, Hyderabad, and other public sector manufacturers are being upgraded with the required infrastructure and technology. Financial support is being provided as a grant from GoI to the tune of approx. Rs 65 Cr to Bharat Biotech’s new Bangalore facility is being repurposed to increase vaccine production capacity.
The following three public sector companies are also being supported to increase the capacity of vaccine production.
1. Haffkine Biopharmaceutical Corporation Ltd, Mumbai-a State PSE under State Govt of Maharashtra.
Financial support of Rs. 65 crores as a grant from GoI is being provided for this facility to make it ready for manufacturing. The facility will have a capacity of 20 million doses per month, once functional.
2. Indian Immunologicals Limited (IIL), Hyderabad –A facility under National Dairy Development Board is being provided with a grant of Rs. 60 crores and
3. Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr a CPSE under the Department of Biotechnology, Government of India is being supported with a grant of Rs. 30 crores to prepare their facility to provide 10-15 million doses per month.
Further, Gujarat Biotechnology Research Centre, Department of Science and Technology Govt. of Gujarat along with Hester Biosciences and OmniBRx has also firmed up its discussions with Bharat Biotech to scale up the COVAXIN technology and to produce a minimum of 20 million doses per month. The technology transfer agreement has been finalized with all manufacturers.
About DBT: The Department of Biotechnology (DBT), under the Ministry of Science & Technology, promotes the use and application of biotechnology in the areas of agriculture, healthcare, animal sciences, environment and industry. It is focused on attaining new heights in biotechnology research, shaping biotechnology into a premier precision tool of the future to create wealth and ensure social justice – especially for the welfare of the poor. www.dbtindia.gov.in
About BIRAC: Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by the Department of Biotechnology (DBT), Government of India as an Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs.www.birac.nic.in
For Further Information: Contact Communication Cell of debt/BIRAC*@DBTIndia@BIRAC_2012